Ivermectin, an fda-approved anti-parasitic agent, was found to be an inhibitor of sars-cov-2 replication in the laboratory.
ivermectin may be effective for the treatment of early-onset mild infections in adult patients.
early viral clearance of sars-cov-2 was observed in ivermectin treated patients.
remission of fever, cough and sore throat did not differ among treatment groups. no severe adverse event was observed